|Astrocyte Pharmaceuticals||The company is a U.S.-based clinical CNS drug development company, is pursuing an innovative neuroprotective strategy of enhancing mitochondrial energy production in astrocytes to protect and repair damaged neurons. Astrocyte is developing the proprietary small molecule pharmaceutical agent AST-004 for acute administration to patients who have suffered a stroke, TBI, or concussion, and for chronic neurodegenerative disorders such as Alzheimer’s disease.|
|WEX Pharmaceuticals Inc.||WEX Pharmaceuticals Inc. (WEX) is a late-stage biopharmaceutical company focused on developing Halneuron®, for the treatment of neuropathic and nociceptive pain. Halneuron is icleared by the US Food Drug Administration and Health Canada to commence pivotal Phase 3 trials for Chemotherapy-Induced Neuropathic Pain (CINP). Halneuron has also demonstrated promising clinical effects in moderate to severe Cancer Related Pain (CRP) trials.|
|Afimmune||Afimmune, headquartered in Dublin, Ireland, is a clinical stage drug discovery and development company focused on the development of biologically active polyunsaturated lipids for the treatment of cardiometabolic diseases.|
Afimmune has assets in various stages of clinical and preclinical development.
Afimmune’s lead compound is the active pharmaceutical substance Epeleuton, a synthetic derivative of the endogenous 15-HEPE (15-Hydroxy-Eicosapentaenoic Acid).
|WinSanTor Inc||WinSanTor is, as mentioned by the USFDA, potentaily the only disease modifying treatments for…. peripheral neuropathy. it is a true unmet need affecting 100s of millions where currently there is no approved treatment. We have strong MOA evidence showing reversal of structural and functional nerve damage. Our lead asset, now in Phase 2, is a repurposing/reformulation of a historicaly safe drug to ensure expedited approval.|
|IMMEDIATE Therapeutics||IMMEDIATE Therapeutics is a clinical stage biotech company dedicated to developing safe and effective therapeutic solutions to reduce heart muscle damage and prevent cardiac arrest in Acute Coronary Syndromes (ACS), the most common cause of death and morbidity across the world.|
|Microvascular Therapeutics||Pioneer in ultrasound contrast agents and theranostics|
|METiS Pharmaceuticals||METiS is the world’s first start-up company to drive drug delivery and formulation development with artificial intelligence. Through the combination of high-throughput test platforms and artificial intelligence computing technologies, it realizes the automation and intelligence of drug delivery and formulation development, and large-scale production New drugs with clinical significance, bringing more good drugs to patients.|
|Sintetica||SINTETICA is a fully integrated private company developing and commercializing sterile injectables as reformulated and repurposed generics for the emergency, ambulatory and critical care units of hospitals and care centers.|